Alnylam’s KARDIA-2 Study Shows Significant Blood Pressure Reductions with Zilebesiran
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced positive results from the Phase 2 KARDIA-2 trial of zilebesiran, an RNAi therapeutic designed to treat hypertension by…